PamGene's NHR platform in major EDCMET Consortium
Metabolic effects of Endocrine Disrupting Chemicals: novel testing METhods and adverse outcome pathways (EDCMET)

PamGene is a part of the exciting EDCMET Consortium (‘Metabolic effects of Endocrine Disrupting Chemicals: novel testing METhods and adverse outcome pathways’), a European Union-funded Project within the Horizon 2020 (H2020) framework. The project is running from January 2019 until December 2023 and is coordinated by Prof. Dr. Anna-Liisa Levonen from the University of Eastern Finland. Project partners from nine European countries will contribute to achieving the scientific goals of EDCMET.

 

Classically, endocrine disrupting chemicals (EDs) are known as compounds which exert adverse effects by interfering with hormone-related signalling pathways. Less attention has been paid to possible effects of chemical substances on metabolic pathways, though metabolic diseases constitute an increasing health concern in Western countries. The objective of the project EDCMET is to develop validated in silico, in vitro and in vivo methods assessing metabolic effects of EDs, with a focus on energy and fat metabolism and nuclear receptors regulating these processes via their interaction with foreign compounds. EDCMET will follow the adverse outcome pathway (AOP) paradigm to identify molecular initiating events (MIE) and predict the emergent adverse biological phenotype, as thorough understanding of the mechanisms leading to adverse metabolic effects of EDs is presently lacking. The project addresses these challenges as it brings together experts in the various fields to meet the common goal to improve the currently available testing methods. EDCMET covers a wide variety of methodologies for novel and improved approaches to address the metabolic effects of EDs, ranging from computational methods, cell culture systems and up-to-date animal models, to epidemiological data to associate the levels of chemicals to ED-related metabolic effects.

 

Within EDCMET, PamGene will be engaged in in vitro experimentation related to functional metabolic profiling of EDs. PamGene offers peptide-array based cell-signaling, mechanism-of-toxicity and nuclear receptor profiling services. PamGene will lead the efforts in developing and validating an EDs screening battery using its nuclear receptor cofactor interaction assays for those nuclear receptors which play a role in metabolism. PamGene as one of the two SMEs in the consortium will take the lead in commercialization efforts of the in silico, in vitro and in vivo methods developed in the EDCMET consortium and thereby extend its existing product offerings.